TIGIT anticorps

N° du produit ABIN2665413

Détail du produit anti-TIGIT anticorps

Antigène: TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT))

Reactivité: Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TIGIT est non-conjugé

Application: Intracellular Flow Cytometry (ICFC)

Purification: The antibody was purified by affinity chromatography.

Clone: 1G9

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TIGIT

Antigène: TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT))

Autre désignation: TIGIT (TIGIT Produits)

Synonymes: anticorps VSIG9, anticorps VSTM3, anticorps WUCAM, anticorps ENSMUSG00000071552, anticorps Vstm3, anticorps RGD1563191, anticorps T-cell immunoreceptor with Ig and ITIM domains, anticorps T cell immunoreceptor with Ig and ITIM domains, anticorps TIGIT, anticorps Tigit

Sujet: T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as V-set and transmembrane domain-containing protein 3 (Vstm3), is a 26 kD, type I transmembrane protein and member of the CD28 family. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. Its ligands are PVR, PVRL2, PVRL3, CD155, and CD112. TIGIT is a negative regulator of NK and T cell activation. Engagement of TIGIT by dendritic cells results in their differentiation into a tolerogenic phenotype, with an increased secretion of IL-10 and a diminished production of IL-12. Mice deficient for TIGIT are more susceptible to autoimmune disease.

Pathways: Cancer Immune Checkpoints